Vir Biotech's Revenue Plummets 80% in 2023, Net Loss Widens

TL;DR

**Vir Biotech's revenue crashed over 80% to $104.9M in 2023, swinging to a $498.8M net loss from near break-even, signaling major headwinds.**

AI Summary

Vir Biotechnology, Inc. reported a significant decrease in total revenues for the fiscal year ended December 31, 2023, dropping to $104.9 million from $517.2 million in 2022 and $1.1 billion in 2021. This decline was primarily driven by reduced collaboration revenue, which fell from $499.9 million in 2022 to $87.8 million in 2023. The company's net loss for 2023 was $498.8 million, a substantial increase from a net loss of $10.9 million in 2022.

Why It Matters

This sharp decline in revenue and widening net loss indicates significant challenges for Vir Biotechnology, potentially impacting its ability to fund future research and development without additional capital.

Risk Assessment

Risk Level: high — The substantial decrease in revenue and significant increase in net loss indicate a challenging financial position and potential operational difficulties for Vir Biotechnology.

Key Numbers

• $104.9M — Total Revenue (for fiscal year 2023, a significant decrease from prior years)
• $498.8M — Net Loss (for fiscal year 2023, a substantial increase from 2022)
• $87.8M — Collaboration Revenue (for fiscal year 2023, down from $499.9M in 2022)

Key Players & Entities

• Vir Biotechnology, Inc. (company) — filer
• $104.9 million (dollar_amount) — total revenue for 2023
• $517.2 million (dollar_amount) — total revenue for 2022
• $1.1 billion (dollar_amount) — total revenue for 2021
• $498.8 million (dollar_amount) — net loss for 2023
• $10.9 million (dollar_amount) — net loss for 2022
• December 31, 2023 (date) — end of fiscal year

FAQ

From the Filing

0001628280-24-006852.txt : 20240226 0001628280-24-006852.hdr.sgml : 20240226 20240226161013 ACCESSION NUMBER: 0001628280-24-006852 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24678794 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 10-K 1 vir-20231231.htm 10-K vir-20231231 0001706431 false 2023 FY P3Y P7Y P7Y http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities 438 0001706431 2023-01-01 2023-12-31 0001706431 2023-06-30 iso4217:USD 0001706431 2024-02-16 xbrli:shares 0001706431 2023-12-31 0001706431 2022-12-31 iso4217:USD xbrli:shares 0001706431 vir:CollaborationRevenueMember 2023-01-01 2023-12-31 0001706431 vir:CollaborationRevenueMember 2022-01-01 2022-12-31 0001706431 vir:CollaborationRevenueMember 2021-01-01 2021-12-31 0001706431 vir:ContractRevenueMember 2023-01-01 2023-12-31 0001706431 vir:ContractRevenueMember 2022-01-01 2022-12-31 0001706431 vir:ContractRevenueMember 2021-01-01 2021-12-31 0001706431 vir:LicenseRevenueMember 2023-01-01 2023-12-31 0001706431 vir:LicenseRevenueMember 2022-01-01 2022-12-31 0001706431 vir:LicenseRevenueMember 2021-01-01 2021-12-31 0001706431 us-gaap:GrantMember 2023-01-01 2023-12-31 0001706431 us-gaap:GrantMember 2022-01-01 2022-12-31 0001706431 us-gaap:GrantMember 2021-01-01 2021-12-31 0001706431 2022-01-01 2022-12-31 0001706431 2021-01-01 2021-12-31 0001706431 us-gaap:CommonStockMember 2020-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001706431 us-gaap:RetainedEarningsMember 2020-12-31 0001706431 us-gaap:NoncontrollingInterestMember 2020-12-31 0001706431 2020-12-31 0001706431 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001706431 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001706431 us-gaap:CommonStockMember 2021-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001706431 us-gaap:RetainedEarningsMember 2021-12-31 0001706431 us-gaap:NoncontrollingInterestMember 2021-12-31 0001706431 2021-12-31 0001706431 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001706431 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001706431 us-gaap:CommonStockMember 2022-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001706431 us-gaap:RetainedEarningsMember 2022-12-31 0001706431 us-gaap:NoncontrollingInterestMember 2022-12-31 0001706431 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001706431 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001706431 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001706431 us-gaap:CommonStockMember 2023-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-12-31